Inkcazo eneenkcukacha
IHepatitis E ibangelwa yintsholongwane yehepatitis (HEV).I-HEV yi-enterovirus eneempawu zeklinikhi kunye ne-epidemiology efana ne-hepatitis A.
I-Anti-HEIgM ifunyenwe kwi-serum ngexesha lesigaba esinzima se-viral hepatitis E kwaye ingasetyenziswa njengesalathisi sokuxilonga kwangaphambili.I-low titer anti-HEIgM inokulinganiswa ngexesha lokuchacha.
IHepatitis E sisifo esosulelayo esiyingozi esidluliselwa ngomlomo welindle.Ukususela ekuqhambukeni kokuqala kwe-hepatitis E e-Indiya ngo-1955 ngenxa yongcoliseko lwamanzi, iye yaxhaphaka eIndiya, eNepal, eSudan, eKyrgyzstan yeSoviet Union kunye ne-Xinjiang e-China.
NgoSeptemba 1989, iNkomfa yaMazwe ngaMazwe yaseTokyo ye-HNANB kunye neGazi yeZifo ezosulelayo ngokusemthethweni yathiywa ngokusemthethweni i-hepatitis E, kunye ne-ejenti ebangelayo, i-Hepatitis E Virus (HEV), iphantsi kwe-taxonomically kwi-genus Hepatitis E virus kusapho lwe-Hepatitis E virus.
(1) Ukufunyanwa kwe-serum ye-anti-HEV IgM kunye ne-anti-HEV IgG: Ukuxilongwa kwe-EIA kusetyenziswa.I-Serum ye-anti-HEV IgG yaqala ukufunyanwa emva kweentsuku ezi-7 emva kokuqala, enye yeempawu zosulelo lwe-HEV;
(2) Ukufunyaniswa kwe-HEV RNA kwi-serum kunye neendle: Ngokuqhelekileyo iisampuli eziqokelelwe kwinqanaba lokuqala lokuqala ziqokelelwa kusetyenziswa uphando lwenethiwekhi yemfundo yesayensi ye-RT-PCR.